4.4 Article

Alliance A082002-a randomized phase II/III trial of modern immunotherapy-based systemic therapy with or without SBRT for PD-L1-negative, advanced non-small cell lung cancer

Journal

CLINICAL LUNG CANCER
Volume 23, Issue 5, Pages E317-E320

Publisher

CIG MEDIA GROUP, LP
DOI: 10.1016/j.cllc.2022.04.004

Keywords

Lung cancer; Stereotactic body radiation therapy; Immunotherapy; Chemotherapy; programmed death-1 ligand negative; advanced stage non-small cell lung cancer

Categories

Funding

  1. National Cancer Institute of the National Institutes of Health [U10CA180821, U10CA180882, UG1CA232760, UG1CA233180, UG1CA233191, UG1CA233253, UG1CA233277, U10CA180820, U10CA180888, U10CA180868]

Ask authors/readers for more resources

This study aims to determine if stereotactic body radiation therapy (SBRT) added to systemic therapy can significantly improve outcomes for patients with advanced stage non-small cell lung cancer (NSCLC) without PD-L1 protein expression. The trial will compare SBRT plus systemic therapy with systemic therapy alone and evaluate progression-free and overall survival. This multi-institutional trial will provide further insight into the efficacy of combining SBRT with systemic therapy.
Introduction: Treatment of advanced stage non-small cell lung cancer (NSCLC) has changed dramatically due to immunotherapy. However, patients without Programmed Death-Ligand 1 (PD-L1) protein expression often benefit less from immunotherapy. This trial is designed to test if stereotactic body radiation therapy (SBRT) to a single tumor site can significantly enhance the outcome of patients with advanced stage PD-L1(-) NSCLC when added to systemic therapy including immunotherapy. Materials and Methods: Alliance A082002 is based on subgroup analysis from the randomized phase II PEMBRO-RT trial., PEMBRO-RT compared pembrolizumab alone or with SBRT and revealed improved progression-free and overall survival (PFS and OS, respectively) in PD-L1(-) patients when adding SBRT (8 Gy x 3 fractions). In A082002, patients without PD-L1 expression will be randomized to SBRT (8 Gy x3) plus systemic therapy vs. systemic therapy alone. The pr imary endpoint of the phase II portion of the tr ial is PFS and will require 100 patients. The primary endpoint of the phase III portion of the trial is OS and will require an additional 284 patients. This trial will clarify whether adding SBRT to systemic therapy can improve PFS and OS in a larger multi-institutional cohort. Several systemic treatment options are allowed including either immunotherapy alone or chemo-immunotherapy. Conclusions: This phase II/III Alliance trial A082002 will test whether the addition of SBRT to a single tumor site will enhance the anti-tumor activity of systemic immunotherapy or chemo-immunotherapy in patients with stage IV PD-L1(-) NSCLC. It is now open in the National Clinical Trials Network (NCTN).

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available